Literature DB >> 24169121

Higher serum iron is associated with increased oxidant stress in HIV-infected men.

Matthew B Crist1, Vlada V Melekhin, Aihua Bian, Ayumi Shintani, Ginger L Milne, Asha R Kallianpur, Leigh A Dageforde, David W Haas, Todd Hulgan.   

Abstract

BACKGROUND: F₂-isoprostanes (F₂-IsoP) are oxidant stress biomarkers that are higher in HIV-infected women than men. We explored whether the effect of hemoglobin (Hgb), serum iron, or anemia on F₂-IsoP is different between HIV-infected women and men.
METHODS: Plasma F₂-IsoP were quantified by gas chromatography/mass spectrometry; clinical and laboratory data were collected at enrollment or from the medical record. Multivariable linear regression was used to assess associations between F₂-IsoP and Hgb, anemia as a dichotomous variable, and serum iron with adjustment for age, sex, race, body mass index, CD4 lymphocyte count, self-reported current smoking status, and antiretroviral therapy.
RESULTS: Compared with men, women had lower Hgb [median: 12.7 (interquartile range: 11.8-13.9) vs. 14.9 (13.7-15.8) g/dL, P < 0.001], lower iron levels [75 (47-97) vs. 90 (69-121) µg/dL, P = 0.004], more anemia (29% vs. 10%, P < 0.001), and higher levels of F₂-IsoP [42 (32-62) vs. 36 (25-46) pg/mL, P < 0.001]. The relationship between iron and F₂-IsoP differed significantly between men and women (interaction P = 0.02). Men had a 21% (95% confidence interval: 8 to 36) increase in F₂-IsoP per interquartile increase in iron (P = 0.001), whereas no relationship was seen among women [-4% (-17 to 13, P = 0.65].
CONCLUSIONS: Although women have overall higher F₂-IsoP than men, a relationship between circulating F₂-IsoP and iron levels was observed in men but not in women with HIV infection. The association between female sex and higher F₂-IsoP is not explained by iron or Hgb levels because the association persists when controlling for these factors. The role of iron in oxidant stress and sex-specific differences among HIV-infected individuals require further study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24169121      PMCID: PMC3816092          DOI: 10.1097/QAI.0b013e3182a60f36

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  35 in total

1.  Elevated iron status strongly predicts mortality in West African adults with HIV infection.

Authors:  Joann M McDermid; Assan Jaye; Maarten F Schim van der Loeff; Jim Todd; Chris Bates; Steve Austin; David Jeffries; Akum A Awasana; Akum A Whittlex; Andrew Prentice
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-01       Impact factor: 3.731

Review 2.  The isoprostanes: unique bioactive products of lipid peroxidation.

Authors:  J D Morrow; L J Roberts
Journal:  Prog Lipid Res       Date:  1997-03       Impact factor: 16.195

3.  Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage.

Authors:  J D Morrow; B Frei; A W Longmire; J M Gaziano; S M Lynch; Y Shyr; W E Strauss; J A Oates; L J Roberts
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

4.  Anemia and survival in HIV infection.

Authors:  R D Moore; J C Keruly; R E Chaisson
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-09-01

5.  Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study.

Authors:  Myron Gross; Michael Steffes; David R Jacobs; Xinhua Yu; Linda Lewis; Cora E Lewis; Catherine M Loria
Journal:  Clin Chem       Date:  2004-10-28       Impact factor: 8.327

6.  Oxidant stress is increased during treatment of human immunodeficiency virus infection.

Authors:  Todd Hulgan; Jason Morrow; Richard T D'Aquila; Stephen Raffanti; Michael Morgan; Peter Rebeiro; David W Haas
Journal:  Clin Infect Dis       Date:  2003-11-19       Impact factor: 9.079

7.  Iron supplementation during human immunodeficiency virus infection: a double-edged sword?

Authors:  T D Clark; R D Semba
Journal:  Med Hypotheses       Date:  2001-10       Impact factor: 1.538

Review 8.  HIV and menopause: a review.

Authors:  Erna Milunka Kojic; Chia-Ching Wang; Susan Cu-Uvin
Journal:  J Womens Health (Larchmt)       Date:  2007-12       Impact factor: 2.681

9.  Body iron store as a predictor of oxidative DNA damage in healthy men and women.

Authors:  Ai Hori; Tetsuya Mizoue; Hiroshi Kasai; Kazuaki Kawai; Yumi Matsushita; Akiko Nanri; Masao Sato; Masanori Ohta
Journal:  Cancer Sci       Date:  2009-10-10       Impact factor: 6.716

10.  Anemia and survival in human immunodeficiency virus.

Authors:  Jens D Lundgren; Amanda Mocroft
Journal:  Clin Infect Dis       Date:  2003       Impact factor: 9.079

View more
  5 in total

1.  Effect of iron supplementation during lactation on maternal iron status and oxidative stress: A randomized controlled trial.

Authors:  Josh M Jorgensen; Zhenyu Yang; Bo Lönnerdal; Caroline J Chantry; Kathryn G Dewey
Journal:  Matern Child Nutr       Date:  2016-11-29       Impact factor: 3.092

2.  Short communication: high cellular iron levels are associated with increased HIV infection and replication.

Authors:  Hsiang-Chun Chang; Marina Bayeva; Babafemi Taiwo; Frank J Palella; Thomas J Hope; Hossein Ardehali
Journal:  AIDS Res Hum Retroviruses       Date:  2014-10-07       Impact factor: 2.205

Review 3.  The isoprostanes--25 years later.

Authors:  Ginger L Milne; Qi Dai; L Jackson Roberts
Journal:  Biochim Biophys Acta       Date:  2014-10-30

4.  Anemia, Iron Status, and HIV: A Systematic Review of the Evidence.

Authors:  Ajibola I Abioye; Christopher T Andersen; Christopher R Sudfeld; Wafaie W Fawzi
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

5.  Antiretroviral Therapy Initiation Alters the Redox System of Asymptomatic HIV-Infected Individuals: A Longitudinal Study.

Authors:  Karen Ingrid Tasca; Juliana Trindade Caleffi; Camila Renata Correa; Mariana Gatto; Francilene Capel Tavares; Caio Cavassan Camargo; Alexandrina Sartori; Mara Biasin; Lenice do Rosário de Souza
Journal:  Oxid Med Cell Longev       Date:  2017-03-21       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.